Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 7/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.41 |
| ▸ | AXL | P30530 | 7/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676705 | 0.86 | AXL (0.39) | SGK1CAMKK2AXLCDK8TNIK | |
| SCHEMBL1713987 | 0.86 | BRD4 (0.32) | — | |
| SCHEMBL1713992 | 0.86 | BRD4 (0.32) | — | |
| SCHEMBL1713625 | 0.85 | JAK2 (0.32) | CYP3A4 | |
| SCHEMBL1713624 | 0.85 | JAK2 (0.32) | CYP3A4 | |
| SCHEMBL1713495 | 0.77 | JAK2 (0.39) | GSK3BCYP3A4 | |
| SCHEMBL1713496 | 0.77 | JAK2 (0.39) | GSK3BCYP3A4 | |
| SCHEMBL1714357 | 0.75 | AXL (0.41) | SGK1CAMKK2AXLCDK8TNIK | |
| SCHEMBL1714356 | 0.75 | AXL (0.41) | SGK1CAMKK2AXLCDK8TNIK | |
| SCHEMBL13676708 | 0.75 | AXL (0.39) | SGK1CAMKK2AXLCDK8TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| EP-2094699-B1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | SGK1 217/4885CAMKK2 305/4885AXL 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.